LAAC Noninferior to NOAC in Anticoagulation-Eligible AF
CHAMPION-AF extends left atrial appendage closure into patients who can tolerate anticoagulation, reframing the device as an elective bleeding-reduction strategy rather than a contraindication-driven fallback.
📅 Journal publication: Jun 4, 2026(online Mar 28, 2026)·Last updated: Oct 4, 2026
Atrial appendage closure reduces bleeding in atrial fibrillation.
Choosing between left atrial appendage closure and anticoagulation is crucial for preventing stroke in atrial fibrillation patients. Device-based closure was noninferior for cardiovascular events and superior for reducing non-procedure-related bleeding compared to NOACs. This study suggests left atrial appendage closure as a viable alternative to NOACs for suitable atrial fibrillation patients, reducing bleeding risks. Left atrial appendage closure offers similar efficacy with less bleeding compared to NOACs.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Doshi SK, Kar S, Nair DG, Waggoner T, Agarwal H, Moussavian M, Kashani A, Oza S, Feldman L, Sadhu A, DeLurgio D, Alli O, Nielsen-Kudsk JE, Yamamoto M, Alkhouli M, Camm AJ, Coylewright M, Gibson CM, Granger CB, Gurol ME, Huber KC, Mansour M, Natale A, Pocock SJ, Reddy VY, Saliba WI, Asch FM, Wehrenberg S, Frost K, Christen T, Sutton BS, Stein KM, Leon MB, Ellenbogen KA, CHAMPION-AF Investigators
Citation:Doshi SK, Kar S, Nair DG, et al. Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation. The New England journal of medicine. 2026;394(21):2083-2094. doi:10.1056/NEJMoa2517213